发布求助
文献互助 智能选刊 最新文献

Best Practice & Research Clinical Haematology最新文献

筛选
英文 中文
Cytokine therapy of acute radiation syndrome 急性放射综合征的细胞因子治疗
IF 2.2 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2024-12-01 DOI: 10.1016/j.beha.2025.101599
Hillard M. Lazarus , Robert Peter Gale
{"title":"Cytokine therapy of acute radiation syndrome","authors":"Hillard M. Lazarus ,&nbsp;Robert Peter Gale","doi":"10.1016/j.beha.2025.101599","DOIUrl":"10.1016/j.beha.2025.101599","url":null,"abstract":"<div><div>Radiological accidents/incidents are common with nearly 400 reported since 1944 exposing about 3000 people to substantial doses of ionizing radiations with 127 deaths. Damage to hematopoietic stem and progenitor cells with resulting bone marrow failure is a common consequence of exposure to whole body acute high-dose and -dose-rate ionizing radiations and is termed hematopoietic-acute radiation syndrome, or H-ARS. Therapy of H-ARS includes transfusions, anti-bacterial and -viral drugs, molecularly-cloned hematopoietic growth factors and hematopoietic cell transplants. We considered the role of recombinant human granulocyte-colony-stimulating factor (rhu G-CSF; filgrastim) and recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF; sargramostim) in the setting of H-ARS. The favorable <em>benefit-to-risk</em> ratio of these drugs over hematopoietic cell transplants suggests giving them soon after exposure to acute high-dose and-dose-rate whole body ionizing radiations.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 4","pages":"Article 101599"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bispecific antibody therapy for lymphoma 淋巴瘤的双特异性抗体治疗
IF 2.2 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2024-12-01 DOI: 10.1016/j.beha.2025.101598
Genevieve M. Gerhard, Gottfried von Keudell
{"title":"Bispecific antibody therapy for lymphoma","authors":"Genevieve M. Gerhard,&nbsp;Gottfried von Keudell","doi":"10.1016/j.beha.2025.101598","DOIUrl":"10.1016/j.beha.2025.101598","url":null,"abstract":"<div><div>The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL. In this review, we focus primarily on Diffuse Large B-cell Lymphoma (DLBCL), highlighting the evolution, comparison, tolerability, ongoing challenges, and future potential of bispecific antibodies that are currently approved or in clinical trials for B-NHL. With the number of anti-lymphoma drugs increasing every year, it is important to optimize clinical trial analysis and design so that outcomes, toxicities, and predictors thereof can be understood and compared amongst therapeutic classes to ensure that patients get the safest and most effective treatments for them at the most appropriate line of therapy.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 4","pages":"Article 101598"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143509201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CARs for lymphoma car - t治疗淋巴瘤
IF 2.2 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2024-12-01 DOI: 10.1016/j.beha.2025.101601
Ishan J. Tatake, Jon E. Arnason
{"title":"CARs for lymphoma","authors":"Ishan J. Tatake,&nbsp;Jon E. Arnason","doi":"10.1016/j.beha.2025.101601","DOIUrl":"10.1016/j.beha.2025.101601","url":null,"abstract":"<div><div>Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized treatment options for B-cell Non-Hodgkin Lymphoma (NHL). CD19-targeting CAR-T cell therapy is approved for treatment in Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. CAR-T cells demonstrate robust and durable responses even in heavily pretreated patients. Clinicians should monitor for Cytokine Release Syndrome (CRS) and Immune Effector Cell Neurotoxicity Syndrome (ICANS), as well as cytopenias, infection, and secondary malignancies. Ongoing questions remain in improving manufacturing efficacy, sequencing CAR-T cells amongst other therapies including bi-specific antibodies (BiTEs), and predicting optimal responders. In addition, novel CARs are being developed with alternative targets or that secrete activating cytokines (i.e. “armored CARs”). CAR-T cells represent an effective lymphoma therapy and should be considered for eligible patients.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 4","pages":"Article 101601"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to “Special issue 37.2 and 37.3 Genetics and Function of HLA and immune-related genes in transplantation and cellular immunotherapy” [Best Pract Res Clin Haematol (2024) 101588] 对 "特刊 37.2 和 37.3 移植和细胞免疫疗法中 HLA 和免疫相关基因的遗传学和功能 "的勘误 [Best Pract Res Clin Haematol (2024) 101588]
IF 2.2 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2024-11-13 DOI: 10.1016/j.beha.2024.101594
Katharina Fleischhauer
{"title":"Erratum to “Special issue 37.2 and 37.3 Genetics and Function of HLA and immune-related genes in transplantation and cellular immunotherapy” [Best Pract Res Clin Haematol (2024) 101588]","authors":"Katharina Fleischhauer","doi":"10.1016/j.beha.2024.101594","DOIUrl":"10.1016/j.beha.2024.101594","url":null,"abstract":"","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 4","pages":"Article 101594"},"PeriodicalIF":2.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation 供体特异性 HLA 抗体与造血细胞移植的相关性
IF 2.2 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 DOI: 10.1016/j.beha.2024.101576
Thuong Hien Tran , Andreas Heinold , Magdalena Spackova , Lien Pham , Matthias Stelljes , Peter Dreger
{"title":"Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation","authors":"Thuong Hien Tran ,&nbsp;Andreas Heinold ,&nbsp;Magdalena Spackova ,&nbsp;Lien Pham ,&nbsp;Matthias Stelljes ,&nbsp;Peter Dreger","doi":"10.1016/j.beha.2024.101576","DOIUrl":"10.1016/j.beha.2024.101576","url":null,"abstract":"<div><p>Advances in hematopoietic cell transplantation have expanded the use of alternative donors such as haploidentical family donors or mismatched unrelated donors. However, donor-specific HLA antibodies (DSA) have been recognized as a significant risk factor of primary graft failure after HLA incompatible transplantation. Therefore, screening for HLA antibodies and taking DSA into consideration in the process of donor search play an increasingly important role in donor selection. If an HLA compatible donor is not available, desensitization may enable a successful transplantation. In this review, we describe the currently most widely used methods for HLA antibody detections including their pitfalls. In addition, we summarize the results of the studies on the impact of preformed DSA on transplant outcomes and their treatment options. Many more and larger studies are needed to clarify laboratory issues as well as immunological and clinical aspects in the management of DSA.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 3","pages":"Article 101576"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000422/pdfft?md5=b49527640064925941dcb5a8e246207a&pid=1-s2.0-S1521692624000422-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From clones to immunopeptidomes: New developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation 从克隆到免疫肽组：造血细胞移植中允许的 HLA-DP 错配特征研究的新进展
IF 2.2 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 DOI: 10.1016/j.beha.2024.101575
Esteban Arrieta-Bolaños
{"title":"From clones to immunopeptidomes: New developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation","authors":"Esteban Arrieta-Bolaños","doi":"10.1016/j.beha.2024.101575","DOIUrl":"10.1016/j.beha.2024.101575","url":null,"abstract":"<div><p>Mismatching at the HLA-DPB1 locus occurs frequently in hematopoietic cell transplantation with unrelated donors. Despite this, HLA-DPB1 allelic mismatches have traditionally not been considered in patient-donor matching. A T-cell epitope (TCE) model for the functional assessment of permissive mismatches at this locus has nevertheless been adopted in clinical practice. While initially based on a hierarchical immunogenicity elucidated from allorecognition by T-cell clones isolated from a patient, newer developments in the understanding of this model's biological basis, including a central role for immunopeptidome divergence between mismatched allotypes, have prompted changes in the assignment of permissiveness, providing the opportunity for a more granular evaluation of graft-<em>versus</em>-host disease and relapse risks according to the nature and directionality of permissive mismatches. How these advances impact the assessment of permissiveness at HLA-DPB1 and potentially the intelligent selection of donors according to the main clinical goal for different patients is the subject of the present review.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 3","pages":"Article 101575"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000410/pdfft?md5=eccbdb3e12a17ab67dc0a72288f21c09&pid=1-s2.0-S1521692624000410-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Special issue 37.3: “Genetics and function of HLA and immune-related genes in hematopoietic cell transplantation and cellular immunotherapy” 第 37.3 期特刊："造血细胞移植和细胞免疫疗法中 HLA 和免疫相关基因的遗传与功能"。
IF 2.2 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 DOI: 10.1016/j.beha.2024.101588
Katharina Fleischhauer MD (Guest Editor: Professor)
{"title":"Special issue 37.3: “Genetics and function of HLA and immune-related genes in hematopoietic cell transplantation and cellular immunotherapy”","authors":"Katharina Fleischhauer MD (Guest Editor: Professor)","doi":"10.1016/j.beha.2024.101588","DOIUrl":"10.1016/j.beha.2024.101588","url":null,"abstract":"","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 3","pages":"Article 101588"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142416703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HLA structure and function in hematopoietic-cell transplantation 造血细胞移植中的 HLA 结构和功能
IF 2.2 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 DOI: 10.1016/j.beha.2024.101564
Effie W. Petersdorf
{"title":"HLA structure and function in hematopoietic-cell transplantation","authors":"Effie W. Petersdorf","doi":"10.1016/j.beha.2024.101564","DOIUrl":"10.1016/j.beha.2024.101564","url":null,"abstract":"<div><p>The degree of HLA compatibility between a patient and donor has formed the basis of donor selection since the development of allogeneic hematopoietic cell transplantation over 50 years ago and has advanced understanding of the basic immunobiology of HLA. New evidence supports a role for germline variation in the patient and the donor that do not require HLA matching for their effects to have clinical consequences. The discovery of novel non-coding polymorphisms, structural features of HLA molecules, and expression provide new models for donor selection and inspire the development of tools for clinical translation. Pairwise effects of HLA ligand/donor NK receptors may play an important role in transplant outcomes and showcase the value of understanding the role played by each constituent of the NK pathway in modulating donor responses to target antigens.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 3","pages":"Article 101564"},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142117699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy 干扰 KIR 和 NKG2A 免疫检查点轴释放 NK 细胞免疫疗法
IF 2.2 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2024-07-31 DOI: 10.1016/j.beha.2024.101568
Nicky A. Beelen , Vera T.C. Valckx , Gerard M.J. Bos , Lotte Wieten
{"title":"Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy","authors":"Nicky A. Beelen ,&nbsp;Vera T.C. Valckx ,&nbsp;Gerard M.J. Bos ,&nbsp;Lotte Wieten","doi":"10.1016/j.beha.2024.101568","DOIUrl":"10.1016/j.beha.2024.101568","url":null,"abstract":"<div><p>Due to their intrinsic ability to eliminate malignant cells, natural killer (NK) cells emerge as a promising immunotherapy for cancer. While clinical studies have affirmed the safety of NK cell infusions and combination therapies have demonstrated encouraging outcomes in hematological malignancies, the efficacy of NK cell immunotherapeutic interventions remains heterogeneous across patient cohorts. Moreover, the implementation of NK cell immunotherapy in solid tumors presents notable challenges. Interfering with key NK cell inhibitory signaling pathways by targeting inhibitory killer cell immunoglobulin-like receptors (KIRs) and CD94/NK group 2 member A (NKG2A), holds promise for unleashing the full potential of NK cell-based immunotherapy. In this review, we provide an overview of the current approaches for interfering with inhibitory KIR and NKG2A signaling, exploring a selection of the multitude of combination strategies available. We discuss the significance of maintaining the delicate balance between achieving optimal suppression of NK cell inhibition and ensuring effective activation of anti-tumor effector function, while preserving the favorable safety profiles. The consideration of strategies to modulate inhibitory signaling pathways associated with KIR and NKG2A presents promising avenues for enhancing the efficacy of NK cell immunotherapy.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 3","pages":"Article 101568"},"PeriodicalIF":2.2,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytomegalovirus in haematopoietic cell transplantation - The troll is still there 造血细胞移植中的巨细胞病毒--巨怪依然存在
IF 2.2 4区 医学
Best Practice & Research Clinical Haematology Pub Date : 2024-07-26 DOI: 10.1016/j.beha.2024.101565
Sebastian Voigt
{"title":"Cytomegalovirus in haematopoietic cell transplantation - The troll is still there","authors":"Sebastian Voigt","doi":"10.1016/j.beha.2024.101565","DOIUrl":"10.1016/j.beha.2024.101565","url":null,"abstract":"<div><p>Patients undergoing allogeneic haematopoietic cell transplantation are prone to complications caused by viral infections. Cytomegalovirus (CMV) considerably impacts transplantation as it frequently requires antiviral intervention that evokes substantial side effects depending on the antiviral drug. Intermittent antiviral treatment may become necessary if CMV DNAemia cannot be permanently suppressed, and drug resistance may emerge that hampers and prolongs treatment. Despite sedulous endeavours, vaccination against CMV is not yet available. This review concisely summarises current approaches in managing CMV infection comprising risk factors, diagnostics including indications for resistance testing, and therapeutic options from antiviral drugs to virus-specific T cells.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 3","pages":"Article 101565"},"PeriodicalIF":2.2,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000318/pdfft?md5=69685ba4c435d6a3fe23e097ee7b9c1c&pid=1-s2.0-S1521692624000318-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141940849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信